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Abstract: Mcl-1 is an anti-apoptotic protein of the Bcl-2 family that is essential for the 
survival of multiple cell lineages and that is highly amplified in human cancer. Under 
physiological conditions, Mcl-1 expression is tightly regulated at multiple levels, involving 
transcriptional, post-transcriptional and post-translational processes. Ubiquitination of Mcl-1, 
that targets it for proteasomal degradation, allows for rapid elimination of the protein and 
triggering of cell death, in response to various cellular events. In the last decade, a number 
of studies have elucidated different pathways controlling Mcl-1 ubiquitination and 
degradation. Four different E3 ubiquitin-ligases (e.g., Mule, SCFβ-TrCP, SCFFbw7 and 
Trim17) and one deubiquitinase (e.g., USP9X), that respectively mediate and oppose Mcl-1 
ubiquitination, have been formerly identified. The interaction between Mule and Mcl-1 can 
be modulated by other Bcl-2 family proteins, while recognition of Mcl-1 by the other E3 
ubiquitin-ligases and deubiquitinase is influenced by phosphorylation of specific residues 
in Mcl-1. The protein kinases and E3 ubiquitin-ligases that are involved in the regulation of 
Mcl-1 stability vary depending on the cellular context, highlighting the complexity and 
pivotal role of Mcl-1 regulation. In this review, we attempt to recapitulate progress in 
understanding Mcl-1 regulation by the ubiquitin-proteasome system. 
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1. Introduction 
Apoptosis is an evolutionarily conserved form of programed cell death that plays a crucial role in 
development, tissue homeostasis and defense against infected and potentially harmful cells. Alterations 
in apoptotic pathways are involved in many human disorders: insufficient apoptosis is necessary for 
tumorigenesis and favors autoimmunity, while increased apoptosis is evident in neurodegenerative 
diseases, AIDS and infertility [1]. Apoptosis results from the activation of a family of cysteine 
proteases, named caspases which are responsible for the dismantling of the cell and the characteristic 
morphological changes of apoptosis. Two alternative pathways for caspase activation have been well 
described. The extrinsic pathway results from the binding of cognate ligands to “death receptors”, 
whereas the intrinsic pathway involves cytochrome c release from mitochondria and formation of a 
multiprotein complex called the “apoptosome” [2]. Mitochondrial outer membrane permeabilization 
(MOMP), which leads to the release of cytochrome c and other apoptogenic factors into the cytosol, is 
controlled by interactions between proteins of the Bcl-2 family [3–5]. In both in the extrinsic and 
intrinsic pathways, the ubiquitin-proteasome system (UPS) plays a major role in cell death regulation 
by controlling the level, or the function, of many proteins of the core apoptotic machinery, notably the 
Bcl-2 family proteins [6–9].  
1.1. The Bcl-2 Family 
Bcl-2-related proteins all contain at least one of the four conserved Bcl-2 homology domains  
(BH1-BH4) which enable protein-protein interactions between the different members of the family. 
Proteins of the Bcl-2 family display either anti-apoptotic or pro-apoptotic functions. The members that 
inhibit apoptosis include Bcl-2, Bcl-xL, Mcl-1, Bfl-1/A1, Bcl-B and Bcl-w. These anti-apoptotic 
proteins and the pro-apoptotic effector members, such as Bax and Bak, share at least three BH domains 
and a similar globular structure. These two groups are thus named multi-domain proteins and they 
mainly reside at the mitochondria. Other pro-apoptotic members possess only the BH3 domain and 
display considerable sequence diversity outside of this region. These numerous “BH3-only” proteins 
transduce the various death stimuli to the mitochondria by binding to anti-apoptotic or pro-apoptotic  
multi-domain Bcl-2 family proteins. In these interactions, the amphipathic α-helical fold formed by the 
BH3 domain of the BH3-only proteins locates into a groove formed by the BH1, BH2 and BH3 
domains of the multi-domain proteins. All BH3-only proteins can act as sensitizers by inactivating 
anti-apoptotic Bcl-2 family proteins, but some of them (e.g., tBid, Bim and Puma) can directly activate 
the pro-apoptotic effector proteins Bax and Bak [5,10]. The differential preferences of BH3-only 
proteins for binding to individual survival Bcl-2 proteins allows the integration of many signaling 
pathways [11]. These interactions primarily occur on intracellular membranes, particularly the 
mitochondrial outer membrane to which many family members are directed by a C-terminal hydrophobic 
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transmembrane domain. It is the resulting balance in activity between anti- and pro-apoptotic proteins 
of the Bcl-2 family which determines the fate of the cell. 
1.2. The Ubiquitin-Proteasome Machinery 
Ubiquitination results from the covalent conjugation of ubiquitin to specific lysine residues  
in substrate proteins, under the sequential action of E1 (ubiquitin-activating enzyme), E2  
(ubiquitin-conjugating enzyme) and E3 (ubiquitin protein-ligase) enzymes. This mono-ubiquitination 
can then be extended by ligation of further ubiquitin molecules to any of the seven lysine residues 
present in ubiquitin, thereby producing ubiquitin chains of various topologies [12]. These 
modifications can have diverse effects on the substrate, ranging from proteasome-dependent 
proteolysis [13] to modulation of protein function, subcellular distribution and/or protein-protein 
interactions [14]. The E3 ubiquitin-ligases confer a high degree of specificity to ubiquitination by 
recognizing the target proteins. These enzymes can be classified into two major groups defined by the 
presence of either a HECT (E6AP carboxyl terminus) or a RING (really interesting new gene)  
domain [15]. For HECT domain E3 ubiquitin-ligases, transfer of ubiquitin from the E2 to a substrate 
lysine involves an obligate thioester intermediate with the active-site cysteine of the C-terminal HECT 
domain. The N-terminal domain, which varies among the different HECT domain proteins, is involved 
in specific substrate recognition. The vast majority of E3 ubiquitin-ligases belong to the group of 
RING-containing E3s [16]. The RING is a Zn2+-coordinating domain defined by a pattern of conserved 
cysteine and histidine residues that form a “cross-brace” structure. The RING domain mediates the 
direct transfer of ubiquitin from the E2 to the substrate by serving as a scaffold that brings E2 and 
substrate together. RING finger E3 ubiquitin-ligases can function as monomers, dimers or multi-subunit 
complexes. Multi-subunit RING E3s are exemplified by the CRL (cullin RING ligase) superfamily [17], 
which includes the SCF complex, consisting of SKP1 (S-phase kinase-associated protein 1), cullin and 
F-box protein, and the more elaborate APC/C (anaphase-promoting complex/cyclosome). In the SCF 
complex, an interchangeable F-box protein confers substrate specificity, while a RING-containing 
subunit binds the E2. The APC/C consists of at least thirteen different subunits, including the E2-binding 
RING finger protein APC11 and one of the two co-activators, Cdc20 and Cdh1, which recognizes the 
substrate. Ubiquitination is a reversible post-translational modification that can be opposed by 
deubiquitinating enzymes (DUBs). These enzymes, which exhibit specificity towards the various 
ubiquitin chain topologies, can be grouped into five distinct families: four cysteine protease families 
and one metalloprotease family [18]. Since the early 1990s, ubiquitination and deubiquitination have been 
reported to modulate key proteins involved in apoptosis regulation [6–9,19], notably the Bcl-2 family 
members [7]. Among them, Mcl-1 has been the focus of extensive studies that we will attempt to 
summarize in this review. 
2. Mcl-1 is a Crucial Prosurvival Protein 
Mcl-1 (Myeloid cell leukemia 1) is an anti-apoptotic member of the Bcl-2 family that was originally 
identified as an immediate early gene expressed during TPA-mediated differentiation of a human 
myeloid leukemia cell line [20]. Since then, Mcl-1 has been shown to be widely expressed in many 
tissues [21]. Among pro-survival Bcl-2-family members, Mcl-1 is unique in that it is essential for early 
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embryonic development and for the survival of multiple cell lineages in the adult [22]. Indeed,  
Mcl-1 deficiency results in peri-implantation embryonic lethality [23]. Moreover, the analysis of  
different conditional KO mice revealed Mcl-1-dependent survival of many cell types including 
lymphocytes [24–26], hematopoietic stem cells [27], neutrophils [28,29], neurons [30,31],  
hepatocytes [32], cardiomyocytes [33] and immunoglobulin-secreting plasma cells [34]. In 
comparison, other anti-apoptotic Bcl-2 family members are more dispensable. 
The pro-survival role of Mcl-1 that is the best documented is the inhibition of MOMP and 
cytochrome c release from mitochondria. The exact mechanism underlying this effect has been 
extensively studied and is a part of the general controversy about Bcl-2 family protein-protein 
interactions. According to the unified model that is being widely accepted [4,5,35], Mcl-1 blocks 
MOMP by inactivating the pro-apoptotic proteins Bak and Bax. Depending on the cellular stress, 
Mcl-1 may either sequester the direct-activator BH3-only proteins Bim, Puma and tBid, or directly 
bind the BH3 domains of Bak and Bax, or act by both mechanisms. On the other hand, Mcl-1 can be 
antagonized by sensitizer BH3-only proteins such as Noxa, which induce dissociation of Bak and Bax 
from Mcl-1 (Figure 1) [4,5]. 
Figure 1. Unified model for Mcl-1 regulation of Bak-dependent mitochondrial outer 
membrane permeabilization (MOMP). Mcl-1 and Bak are constitutively anchored to the 
outer mitochondrial membrane (OMM). Mcl-1 can directly bind Bak and maintain it in an 
inactive conformation. Alternatively, Mcl-1 can sequester direct activator BH3-only proteins, 
such as Bim, and prevent them from activating Bak. Sensitizer BH3-only proteins, such as 
Noxa, can relieve Bak inhibition by competing with Mcl-1 for binding the BH3 domain of 
Bak. Activated Bak forms pore in the OMM to release cytochrome c, activate caspases and 
induce apoptosis. Similar mechanisms are relevant for Bax/Mcl-1 interactions. 
 
Pro-survival functions of Mcl-1 extend beyond inhibition of cytochrome c release. Indeed, recent 
data suggest that Mcl-1 is also involved in autophagy regulation [36,37], by interacting with the  
BH3-containing autophagy inducer Beclin-1 [38,39]. Moreover, an N-terminally truncated form of 
Mcl-1, which is imported into the mitochondrial matrix, has been found to promote the maintenance of 
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normal mitochondrial morphology and energy production, thereby reducing the production of 
deleterious reactive oxygen species [22,33,40]. 
Due to its crucial role in cell survival, Mcl-1 has a very high oncogenic potential. In fact, Mcl-1 is 
one of the most highly amplified genes across a variety of solid and haematological human 
malignancies [41]. In many cancers, Mcl-1 appears to be essential for cancer cells to overcome 
oncogenic stress-induced apoptosis. For example, Mcl-1 is critical for the development and 
maintenance of acute myeloid leukemia [42,43]. Furthermore, a high level of Mcl-1 is often associated 
with chemotherapeutic resistance and relapse [44,45]. Notably, Mcl-1 is responsible for the resistance 
to the new generation of BH3 mimetic cancer therapies, including ABT-737 and ABT-263, which bind 
to the anti-apoptotic proteins Bcl-2, Bcl-xL and Bcl-w to disrupt their interaction with the pro-apoptotic 
Bcl-2 family members [46–48]. Thus, Mcl-1 is an attractive and potential therapeutic target in a 
number of malignancies and is the focus of many studies (reviewed in [22,49]). 
3. Multi-Level Regulation of Mcl-1 
As Mcl-1 is essential for the survival of multiple cell lineages, and as Mcl-1 overexpression 
contributes to tumorigenesis, it is of crucial importance that its level and function are strictly 
controlled. Indeed, Mcl-1 is submitted to complex transcriptional, post-transcriptional and post-
translational regulation processes. 
3.1. Transcriptional, Post-Transcriptional and Translational Regulation of Mcl-1 
Transcriptional regulation of Mcl-1 has been extensively studied (for reviews, see [50,51]). 
Multiple growth factors and cytokines, acting on a number of well-known signal transduction 
pathways (e.g., MAP kinases, PI3K/Akt and JAK/STAT) and downstream transcription factors, have 
been shown to induce Mcl-1 transcription, whereas the Mcl-1 promoter has been reported to be 
directly repressed by E2F1 [52]. Mcl-1 is also subject to post-transcriptional and translational 
regulation. For example, the mRNA of Mcl-1 can be alternatively spliced to produce two pro-apoptotic 
shortened forms of Mcl-1, named Mcl-1S and Mcl-1ES, which do not interact with any Bcl-2 family 
members, except with full length Mcl-1 [53,54]. Moreover, the rate of Mcl-1 translation is tightly 
regulated and the Mcl-1 mRNA has a very short half-life [55]. Several miRNAs have been shown to 
inhibit the translation of the Mcl-1 transcript. One well-documented example is miR29 which reduces 
Mcl-1 protein expression by directly binding the Mcl-1 3'UTR [56]. Moreover, a screen for miRNAs 
that sensitize cells to ABT-263 identified 12 miRNAs that reduce Mcl-1 protein expression [57]. The 
RNA binding protein CUGBP2 can also bind to Mcl-1 mRNA 3'UTR and inhibits its translation [58]. 
In addition, eIF2α and mTORC1 have been found to modulate Mcl-1 translation, thereby coupling 
global control of mRNA translation to apoptosis regulation [59,60]. In these different examples, 
increased expression of full-length Mcl-1 resulted in improved cell survival, whereas inhibition of its 
expression was systematically associated with cell death induction or sensitization to apoptosis. 
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3.2. Post-Translational Regulation of Mcl-1 
Unlike other Bcl-2-related survival proteins, Mcl-1 harbors a long unstructured N-terminus that 
appears to be involved in different post-translational modifications of Mcl-1 (Figure 2) [51]. For 
example, it has been shown that, during apoptosis, Mcl-1 protein can be cleaved by caspases and 
granzyme B, at two distinct sites (Asp127 and Asp157) within the N-terminus [61–65]. Some studies 
reported that cleavage at these sites impairs the anti-apoptotic properties of Mcl-1 [61,63], or even 
converts it into a pro-apoptotic protein [62,65]. Cleavage of Mcl-1 thus appears to be a process through 
which apoptotic cells can inactivate residual Mcl-1 that could act as a brake to the achievement of cell 
death. The N-terminus of Mcl-1 contains PEST regions [20], enriched in proline (P), glutamate (E), 
serine (S) and threonine (T) residues, which are common features of rapidly degraded proteins [66]. These 
regions contain the two caspase cleavage sites of Mcl-1 and many phosphorylation sites (Figure 2). 
Differential phosphorylation of Mcl-1 at specific sites has been reported to result in different 
outcomes. For example, the cell cycle-dependent phosphorylation of Ser64 by CDK1, CDK2 and 
JNK1 enhances the anti-apoptotic function of Mcl-1 by increasing its interaction with pro-apoptotic 
members of the Bcl-2 family, without modifying its half-life [67]. Two independent groups have also 
shown that Mcl-1 phosphorylation at Thr92 and Thr163, stimulated by TPA-induced ERK activation, 
stabilizes Mcl-1 in some cancer cell lines [68–70]. Likewise, Ser121 and Thr163 have been found to 
be phosphorylated by JNK [71,72]. In hepatocytes, this JNK-mediated phosphorylation stabilizes Mcl-1 
and affords protection against TNF-induced apoptosis [72], whereas in endothelial cells submitted to 
oxidative stress, this phosphorylation reduces the anti-apoptotic effect of Mcl-1 [71]. Moreover, 
phosphorylation of Mcl-1 at Ser155, Ser159 and Thr163, in a different cellular context, has been 
shown to favour Mcl-1 degradation by the UPS, as discussed below.  
Figure 2. Schematic representation of the human Mcl-1 protein showing the functional 
regions and post-translational modification sites. These include the transmembrane domain 
(TM), Bcl-2 homology domains (BH1-4), weak (lower case) and strong (upper case) PEST 
sequences, sites of ubiquitination (Ub), caspase cleavage and phosphorylation sites. 
 
4. Control of Mcl-1 Protein Level by the Ubiquitin-Proteasome System 
One of the most prominent features of Mcl-1, that sets it apart from the other anti-apoptotic proteins 
of the Bcl-2 family, is its short half-life. The rapid degradation of Mcl-1 was first attributed to the 
proteasome in 2003 by two independent groups, in HeLa cells undergoing apoptosis following UV 
irradiation [73] and adenovirus infection [74]. This was later confirmed by other groups in different 
systems [75–77]. It appeared at that time that the elimination of Mcl-1 was required for the initiation of 
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apoptosis. Indeed, proteasome inhibitors could block the elimination of Mcl-1 and prolong survival of 
Mcl-1 expressing cells, whereas they were unable to prevent apoptosis after Mcl-1 knock-down [73]. 
Then, the poly-ubiquitination of Mcl-1 was demonstrated and five lysine residues involved in Mcl-1 
ubiquitination were identified [78] (Figure 2). In the following years, a number of studies described 
how these mechanisms could be regulated by different enzymes. 
4.1. The E3 Ubiquitin-Ligases of Mcl-1 
To date, five E3 ubiquitin-ligases have been involved in the ubiquitination of Mcl-1, targeting it for 
proteasomal degradation, four of which were demonstrated to directly ubiquitinate Mcl-1. 
4.1.1. Mule 
The first E3 ubiquitin-ligase of Mcl-1 was identified in 2005, by a biochemical fractionation strategy 
using in vitro ubiquitination of Mcl-1 as a read-out [78]. It was named Mule for “Mcl-1 ubiquitin ligase 
E3” but was originally known as LASU1 and ARF-BP1. Mule was identified in parallel in a genome wide 
search for new BH3-containing proteins [79], as it contains a well-conserved BH3 domain. It is of note 
that the BH3 domain of Mule interacts with Mcl-1 but not with Bcl-2, Bcl-xL or Bax [78,79]. Mule is a 
480 kDa protein that belongs to the HECT domain family of E3 ubiquitin-ligases. Mule has been 
demonstrated to ubiquitinate Mcl-1 in vitro and to be necessary for Mcl-1 poly-ubiquitination in HeLa 
cells [78,79]. Indeed, inhibition of Mule expression by RNA interference stabilized Mcl-1 protein, 
resulting in an attenuation of DNA damage-induced apoptosis [78]. 
Mule requires its BH3 domain to target Mcl-1 for rapid degradation [78,79]. However, the Mule 
BH3 peptide has a very low binding affinity for Mcl-1 compared to BH3 peptides from other Mcl-1 
binding partners (Bak, Bim, Bid, Puma and Noxa) [80]. These BH3 peptides should thus easily 
displace Mule from Mcl-1. Indeed, overexpression of Bim [81] or Puma [82] has been shown to 
stabilize Mcl-1 by preventing its interaction with Mule [79] (Figure 3), whereas knock-down of Bim 
increased Mcl-1 degradation [83]. Conversely, binding of Noxa to Mcl-1 was found to trigger the 
proteasomal degradation of Mcl-1 [77,81], by favoring its interaction with Mule [84] (Figure 3). The 
differential effects of the two BH3-only proteins Bim and Noxa seem to rely on a discrete C-terminal 
sequence of the Noxa BH3 domain [81]. Formation of the Noxa/Mcl-1 complex might promote the 
binding of Mule through a distinct mechanism than docking of the Mule BH3 into the BH3-binding 
groove of Mcl-1. Indeed, a second site of interaction with Mule exists within the N-terminal 30 amino 
acids of Mcl-1 [80] (Figure 3). This should permit Mule to bind Mcl-1 even when a BH3-only protein 
interacts with Mcl-1. 
In cultured cell lines, Mule seems to be responsible for constitutive Mcl-1 degradation [78,79]. 
However, target gene deletion in the mouse, suggests that Mule-dependent ubiquitination of Mcl-1 is 
induced only by specific stimuli. Indeed, Mule attracted considerable interest because it targets many 
substrates such as p53, c-Myc, cdc6 and N-Myc, in addition to Mcl-1 (reviewed in [85]). Therefore, 
several conditional knockout mice have been generated. It appears that basal Mcl-1 protein level is 
largely unaffected in Mule-deficient cells [85,86]. In contrast, etoposide-induced degradation of Mcl-1 
and apoptosis are efficiently blocked by Mule deficiency [86]. This suggests that Mcl-1 degradation 
may involve other E3 ubiquitin-ligases or ubiquitin-independent processes, depending on the conditions.
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4.1.2. Phosphorylation-Dependent Degradation of Mcl-1 
Several independent studies have shown that phosphorylation of Mcl-1 by GSK3 (Glycogen 
Synthase Kinase 3) at Ser155, and/or Ser159 leads to significant decrease in Mcl-1 protein level [87–92]. 
In this context, it was demonstrated that prior phosphorylation of Mcl-1 by JNK at Thr163 (Thr144 in 
mouse) is required for the subsequent phosphorylation of Mcl-1 by GSK3 [90] (Figure 3). Indeed, 
priming phosphorylation of the GSK3 consensus site is often required for the docking of the protein 
kinase to its substrates [93]. Phosphorylation of Mcl-1 by the coordinated activity of JNK and GSK3 
appears to create a phosphodegron mediating the proteasomal degradation of Mcl-1. Indeed, 
phosphorylation-defective mutations of these different serine and threonine residues stabilized Mcl-1 
and increased protection from apoptosis following growth factor withdrawal [89,92], expression of 
constitutively active GSK3 [87], UV irradiation [90] and anti-cancer drugs [87,88]. In some cases, 
Mcl-1 ubiquitination was also shown to be reduced by phosphorylation-defective mutations suggesting 
that Mcl-1 degradation promoted by phosphorylation is ubiquitin-dependent [87–89,92]. Although the 
studies mentioned above all showed that Thr163 phosphorylation promotes Mcl-1 degradation [87–92], 
others reported that phosphorylation by ERK at the same site stabilizes Mcl-1 [48,68–70]. A possible 
explanation for this apparent discrepancy has been recently proposed [70]. Indeed, studies showing a 
stabilization effect have been performed in various cancer cell lines in which Mcl-1 degradation was 
found to be independent of the GSK3 pathway [70]. This is consistent with emerging findings showing 
that Mcl-1 degradation through this pathway is impaired in many different types of cancer [69,94]. 
Overall, Thr163 phosphorylation can prime GSK3-targeted Mcl-1 degradation to promote death in 
normal cells, whereas in cancer cells in which degradation is not dependent on this pathway,  
ERK-mediated phosphorylation of Thr163 is associated with Mcl-1 stabilization and drug resistance. 
4.1.3. SCFβ-TrCP 
The first E3 ubiquitin-ligase accounting for GSK3-dependent proteasomal degradation of Mcl-1 
was identified as SCFβ-TrCP (beta-transducin repeats-containing protein) [87]. Indeed, it was 
demonstrated that Mcl-1 phosphorylation at Ser155, Ser159 and Thr163 by GSK3 facilitates its 
association with the F-box protein β-TrCP [87] (Figure 3). Moreover knock-down of β-TrCP increased 
Mcl-1 levels, whereas overexpression of β-TrCP induced Mcl-1 ubiquitination in a phosphorylation- 
and F-box-dependent manner. In addition, the SCFβ-TrCP complex was able to ubiquitinate Mcl-1 in 
vitro [87]. The role of this SCF E3 ubiquitin-ligase in the GSK3-dependent ubiquitination and 
degradation of Mcl-1 has recently been confirmed in lung cancer cell lines undergoing apoptosis 
following Akt inhibition [95]. Interestingly, SCFβ-TrCP has also been reported to target BimEL for 
degradation in a phosphorylation-dependent manner [96]. Apart from these two Bcl-2 family members, 
SCFβ-TrCP ubiquitinates several substrates that are involved in cell division regulation and various 
transduction pathways, which, in turn, are essential for many aspects of tumorigenesis [97]. 
4.1.4. SCFFbw7 
Another SCF E3 ubiquitin-ligase, containing the F-box protein Fbw7 (F-box and WD repeat 
domain-containing 7) as a substrate-recognition component, has also been implicated in Mcl-1 
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ubiquitination [88,98]. Fbw7 is a well-characterized tumor suppressor which is frequently lost in 
diverse types of cancers. The SCFFbw7 complex targets numerous oncoproteins including c-Myc, 
cyclin E, Notch and c-Jun for ubiquitination and degradation [99]. Two independent studies 
additionally showed that SCFFbw7 mediates Mcl-1 ubiquitination in a phosphorylation-dependent 
manner [88,98] (Figure 3). Indeed, loss of Fbw7 in both human and mouse resulted in accumulation of 
Mcl-1, due to increased half-life, providing resistance to different chemotherapeutics [88,98]. In contrast, 
reintroduction of wild type Fbw7 dramatically reduced Mcl-1 levels and decreased its stability [88,98]. 
Moreover, recombinant Mcl-1 was ubiquitinated in vitro by the reconstituted Fbw7-containing SCF 
complex [98]. In both studies, mutation of the phosphorylation sites Ser159 and Thr163 impaired the 
interaction between Mcl-1 and Fbw7 and reduced Mcl-1 degradation [88,98]. However, the protein 
kinases directing Mcl-1 recruitment to Fbw7 differed from one study to another. In asynchronous cells, 
pharmacological inhibition of GSK3 decreased the binding of Fbw7 to Mcl-1, and Fbw7 promoted 
Mcl-1 ubiquitination when it was co-transfected with GSK3 [88] (Figure 3). However, during mitotic 
arrest, activities of JNK, p38, CKII and CDKI, but not GSK3, were found to regulate Mcl-1 
degradation, by phosphorylating Mcl-1 and promoting Fbw7 binding [98,100]. In these conditions, 
JNK, p38 and CKII directly phosphorylated Mcl-1, while CDK1 indirectly enhanced phosphorylation 
of Mcl-1 at Ser121, Ser159 and Thr63, by phosphorylating Thr92, and thereby driving the dissociation 
of the phosphatase PP2A from Mcl-1 [98,100] (Figure 3). Therefore, the kinases involved in the 
targeting of Mcl-1 by Fbw7 seem to differ depending on the cellular context. 
4.1.5. APC/CCdc20 
During prolonged mitotic arrest, the multi-subunit RING E3 ubiquitin-ligase APC/CCdc20 has also 
been involved in Mcl-1 degradation [101], in addition to SCFFbw7. Indeed, in cells arrested in mitosis 
by microtubule poisons, Mcl-1 proteasomal degradation was found to depend on the substrate-recognition 
co-activator Cdc20, and to require prior phosphorylation of Mcl-1 at Thr92 by CDK1/cyclin B1 [101] 
(Figure 3). However this phosphorylation did not modify the interaction between Mcl-1 and Cdc20, 
and there is no firm evidence as yet that APC/CCdc20 directly mediates Mcl-1 ubiquitination. 
Nevertheless, stabilization of Mcl-1 by mutation of Thr92 inhibited apoptosis induced by prolonged 
mitotic arrest [101]. Therefore, control of Mcl-1 instability by APC/CCdc20 constitutes a direct link 
between the regulation of mitosis and the temporal control of apoptosis [100]. In a normal mitosis, the 
level of Mcl-1 steadily decreases but the reduction in Mcl-1 is insufficient to trigger apoptosis, 
whereas during prolonged mitotic arrest, the level of Mcl-1 eventually drops below a protective 
threshold and apoptosis is initiated. 
4.1.6. Trim17 
The latest E3 ubiquitin-ligase of Mcl-1 that has been formerly identified is Trim17 (Tripartite motif 
containing 17) [92]. Trim17 is a member of the TRIM family that constitutes one of the largest classes 
of single-protein RING-containing E3 ubiquitin-ligases [102,103]. Trim17, also known as terf (testis 
RING finger protein) was first isolated from rat and human testis cDNA libraries [104], but it is also 
expressed in spleen, thymus and to a lesser extent in liver, kidney and brain [105]. Little is known 
about the cellular function of Trim17. It has been implicated in the regulation of cell proliferation, 
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possibly by promoting the degradation of the kinetochore protein ZWINT [106]. In addition, Trim17 
expression has been demonstrated to be both necessary and sufficient for neuronal apoptosis [107]. 
This pro-apoptotic effect appears to depend on the E3 ubiquitin-ligase activity of Trim17 and on the 
Bax-dependent mitochondrial pathway [107]. In apoptotic neurons deprived of survival factors, as 
described in other cell types [87–91], ubiquitination and degradation of Mcl-1 depend on its prior 
phosphorylation by GSK3 [92]. Knock-down of Trim17 expression increased the protein level and 
half-life of Mcl-1, and reduced its ubiquitination level in neurons. In contrast, overexpression of 
Trim17 decreased the protein level of Mcl-1 in a proteasome-dependent manner. This effect was 
abolished by inhibition of GSK3 and JNK, and by phosphorylation-defective mutations of Ser140 and 
Thr144 of mouse Mcl-1 (corresponding to Ser159 and Thr163 in human Mcl-1) [92]. Moreover 
Trim17 could ubiquitinate recombinant Mcl-1 in vitro [92]. Impairment of Mcl-1 phosphorylation, 
either by kinase inhibition or point mutations, not only decreased Mcl-1 ubiquitination and 
degradation, but also disrupted the physical interaction between Trim17 and Mcl-1, the resulting 
stabilization of Mcl-1 increasing its neuroprotective effect [92]. Therefore, Trim17 appears to be a 
physiological E3 ubiquitin-ligase of Mcl-1 in neurons that requires phosphorylation at Ser159 and 
Thr163 to bind Mcl-1 (Figure 3). Nonetheless, Trim17 expression is not restricted to neurons, and it is 
possible that it mediates Mcl-1 ubiquitination in other cell types. 
4.2. Deubiquitination of Mcl-1 by USP9X  
Ubiquitination is a reversible event that can be counteracted by specific enzymes. A deubiquitinase 
from the USP family, USP9X (ubiquitin specific peptidase 9 X-linked), was identified among proteins 
co-immunoprecipitating with Mcl-1 [108]. It has been shown to remove poly-ubiquitin chains from 
Mcl-1, thereby stabilizing it and leading to apoptosis resistance. Indeed, knock-down of USP9X reduced 
the half-life of Mcl-1 and increased its conjugation to Lys48-linked poly-ubiquitin chains [108] that 
generally target proteins for proteasomal degradation. USP9X also deubiquitinated Mcl-1 in vitro, and 
generated free mono-ubiquitin [108]. Therefore, USP9X appears to stabilize Mcl-1 by removing its 
degradative Lys48-linked poly-ubiquitin chains. Direct binding of USP9X was essential for Mcl-1 
stabilization. Interestingly, phosphorylation-defective mutations of the Mcl-1 residues Ser155, Ser159 
and Thr163 to alanines enhanced the interaction between Mcl-1 and USP9X. In contrast, phosphomimetic 
mutations of the three residues to aspartic acids decreased the interaction [108]. Moreover, inhibition 
of PI3K, in order to activate GSK3, also disrupted the binding of USP9X to Mcl-1, whereas GSK3 
inhibition prevented UV-induced dissociation of USP9X from Mcl-1 [108]. Therefore, 
phosphorylation at Ser155, Ser159 and Thr163 not only drives the binding of E3 ubiquitin-ligases such 
as SCFβ-TrCP, SCFFbw7 or Trim17, but also disrupts the binding of the deubiquitinase USP9X (Figure 3). 
It is thus possible that E3 ubiquitin-ligases and USP9X compete for Mcl-1 binding at this crucial 
phosphodegron. 
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Figure 3. Regulation of Mcl-1 stability. Mcl-1 can be phosphorylated by several protein 
kinases (in blue) at indicated residues. In interphase or post-mitotic cells, JNK 
phosphorylates Thr163 which primes Mcl-1 for phosphorylation by GSK3 at Ser159 and 
Ser155. During prolonged mitotic arrest, p38, CKII and JNK phosphorylate Ser121, 
Ser159 and Thr163. CDK1 may indirectly enhance phosphorylation at these sites by 
phosphorylating Thr92, thereby triggering the dissociation of the phosphatase PP2A that 
would otherwise dephosphorylate Mcl-1. Phosphorylation of Ser155, Ser159 and Thr163 
drives the recognition of Mcl-1 by its E3 ubiquitin-ligases SCFβ-TrCP, SCFFbw7 and Trim17 
(in black). In addition, phosphorylation at Thr92 is required for Cdc20-mediated 
ubiquitination of Mcl-1, although direct ubiquitination of Mcl-1 by APC/CCdc20 has not 
been demonstrated. In addition, the E3 ubiquitin-ligase Mule can interact either with the  
C-terminus of Mcl-1 through its BH3 domain, or within the N-terminal 30 amino acids of 
Mcl-1. Binding of Mule does not depend on Mcl-1 phosphorylation but it can be inhibited 
by the BH3-only proteins Bim and Puma. In contrast, Noxa increases the association 
between Mule and Mcl-1 through an as yet unknown mechanism. Ubiquitination of Mcl-1 
targets it for proteasomal degradation. It can be opposed by the deubiquitinase USP9X that 
directly removes degradative Lys-48-linked polyubiquitin chains from Mcl-1, which results 
in Mcl-1 stabilization. Phosphorylation at Ser155, Ser159 and Thr163 inhibits the binding 
of USP9X to Mcl-1. In cancer cells in which Mcl-1 degradation is not dependent on GSK3, 
ERK-mediated phosphorylation of Thr163 stabilizes Mcl-1 (not depicted here). 
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4.3. Ubiquitin-Independent Degradation of Mcl-1  
The involvement of ubiquitination in Mcl-1 proteasomal degradation has been questioned in a study 
using a Mcl-1 mutant in which all 14 lysine residues were replaced by arginines (Mcl-1KR) [109]. This 
mutant protein could not be ubiquitinated. However, it was eliminated by the proteasome at a rate 
similar to wild type Mcl-1, when stably expressed in Mcl-1-deleted MEFs. Importantly, the half-lives 
of wild type Mcl-1 and Mcl-1KR were similar under basal conditions, following UV irradiation and 
even when a constitutively active form of Akt was co-expressed [109]. Moreover, the degradation of 
wild-type Mcl-1 was not affected when the E1 activity was blocked, whereas the half-life of p53 was 
strongly increased in these conditions [109]. To further assess the role of ubiquitination in Mcl-1 
degradation in vivo, transgenic mice expressing epitope-tagged versions of wild-type Mcl-1 or Mcl-1KR 
were generated. In thymocytes and T lymphocytes derived from these mice, both forms of Mcl-1 were 
degraded at a similar rate [109]. Lastly, unmodified, in vitro-translated Mcl-1 could be degraded in a 
cell-free system by the 20S proteasome in the absence of ubiquitination [109]. This work thus indicates 
that Mcl-1 can be directly targeted by the proteasome, in an ubiquitin-independent manner, as it has 
been reported for other proteins [110,111]. 
However, these observations do not exclude the possibility that ubiquitination can accelerate Mcl-1 
elimination in response to certain apoptotic stimuli. Indeed, overexpression of Mule enhanced 
degradation of wild type Mcl-1 whereas it did not influence the turn-over of Mcl-1KR [109]. In 
addition, mutagenesis of critical lysine residues has been found by others to decrease ubiquitination 
and extend the half-life of Mcl-1 in different cell types [78,88,92]. This supports the notion that 
ubiquitination of Mcl-1 is required for its proteasomal degradation, at least in some conditions. In 
some studies, the proteasomal degradation of Mcl-1 appeared to be constitutive, as its half-life was the 
same in the presence or the absence of the death stimuli [73]. However, many others studies reported 
that the degradation of Mcl-1 was accelerated during apoptosis [74,88,98], notably in growth-factor 
dependent cells [75,87,89,91,92], suggesting that the degradation of Mcl-1 can be accelerated by pro-
apoptotic stimuli. Moreover the half-life of Mcl-1 was shown to be modulated by silencing of the 
Mule, β-TrCP, Fbw7 and Trim17 E3 ubiquitin-ligases, as well as the USP9X deubiquitinase 
[78,87,88,92,98,108]. Overall, it is possible that Mcl-1 is normally degraded in an ubiquitin-dependent 
manner, notably in response to cellular stresses. However, if Mcl-1 ubiquitination is blocked, its 
degradation may still occur normally by an alternative ubiquitin-independent mechanism. 
5. Conclusions 
Accumulating evidence indicates that Mcl-1 is a critical pro-survival protein for a myriad of cell 
types, under both physiological and malignant conditions. Therefore, it is not surprising that Mcl-1 
protein level is strictly controlled in normal cells, and that cancer cells have a vast arsenal to ensure 
high levels of Mcl-1 and thereby escape apoptosis. Mcl-1 expression is regulated at multiple levels. 
The proteosomal degradation provides the protein with the unique ability to immediately respond to 
environmental signals and switch cell fate from survival to apoptosis. Highlighting the importance of 
this process, a plethora of pathways and enzymes have been found to modulate the ubiquitination and 
degradation of Mcl-1. Over the past few years, five E3 ubiquitin-ligases, one deubiquitinase, more  
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than six protein kinases and ubiquitin-independent proteasomal degradation have been implicated in 
the regulation of Mcl-1 stability. The relative contributions of these different mechanisms are still 
unclear. The protein kinases involved in the recognition of Mcl-1 by some E3 ubiquitin ligases seem to 
depend on apoptotic stimuli [88,98]. Likewise, the E3 ubiquitin-ligases involved in Mcl-1 
ubiquitination seem to vary depending on specific cell types and death signals. For example, Mule 
activity is not implicated in GSK3-dependent ubiquitination of Mcl-1 [78,87], or in Mcl-1 degradation 
during mitotic arrest [98,101]. Moreover, β-TrCP does not appear to play a role in Mcl-1 degradation, 
in the models in which Fbw7 was identified as a Mcl-1 E3 ubiquitin-ligase [88,98]. Therefore, 
different sets of kinases and E3 ubiquitin-ligases appear to control Mcl-1 levels, allowing different cell 
types to switch to either survival or apoptotic mode in response to various stresses. Future studies 
delineating the relative contributions of these different players in regulating Mcl-1 protein levels in 
specific conditions may help us develop more effective therapeutic strategies for the treatment of 
certain malignancies. 
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